Camille Sullivan Normal [TOP] Full Movie
Blaine Quintal
Yet there is little published guidance about how to interpret RCI output for batteries with multiple indices. For any RCI, the expected false-positive rate is determined by the confidence interval (CI) applied to that RCI. For example, an RCI with a 90% confidence level should classify 5% of normal, healthy individuals as significantly declined from baseline (and, likewise, 5% as significantly improved). Similarly, 80% and 95% CIs should classify 10% and 2.5%, respectively, of normal individuals as significantly declined on average. Clinicians should select thresholds for significance according to their preferences for balancing sensitivity and specificity, with more lenient criteria expected to identify more impairment in concussed athletes (ie, increasing sensitivity) while inevitably also falsely identifying more healthy individuals as impaired (ie, diminishing specificity).
Data were simulated using a modified version of the Monte Carlo procedure described by Crawford et al.12 Broadly, Monte Carlo simulation involves repeated random sampling from 1 or more data sets to estimate the probability of an event of interest. For the current study, this required simulating data sets to match important aspects of potential concussion-assessment batteries (eg, number of indices) and observing how often certain outcomes occurred across simulations. Specifically, the aim was to identify how varying the length of a test battery (conceptualized as the number of indices being interpreted) and the impairment criteria (eg, 80% versus 90% CI) influences the proportion of normal individuals deemed impaired on 1 or more indices in the battery. In order to best estimate these base rates for a particular set of measures, one needs to know the correlations among the measures (in this case, RCIs), which have not been published for the available concussion-assessment batteries. Thus, the primary aim of this analysis was to demonstrate the relationship among test battery length, impairment criteria, and base rates of impairment rather than to definitively estimate the true base rates for any particular assessment tool.
Figure 1 illustrates the relationship among test battery length, impairment criteria, and the expected false-positive rate for RCIs that are uncorrelated. As expected, the estimated rate of impairment increased substantially as the number of subtests/RCIs in the test battery increased and as the threshold for classifying scores as impaired became more lenient. For example, in a battery with 5 uncorrelated RCIs and at a confidence level of 80%, 41% of healthy individuals would be expected to produce at least 1 RCI indicating a decline from baseline, with only 8% of individuals declining significantly on 2 or more tests and 1% declining on 3 or more tests. Once the number of indices increases to 7, the majority of normal individuals (52%) would be expected to show 1 or more significant declines when using RCIs with 80% CIs. For any given test battery, these rates decrease as one tightens the threshold for significance of each index in the battery (eg, for the given example of a test that produces 5 RCIs, the percentage of healthy individuals showing significant decline on 1 or more subtests falls to 23% and 12% when using a 90% or 95% CI for each RCI, respectively). Note that the percentages reported also reflect the expected base rates of significant improvement on retesting.
Expected percentage of normal, healthy individuals who would be classified as impaired on uncorrelated reliable change indices (RCIs), stratified by number of indices in a test battery and number of RCIs required to classify an individual as impaired. Abbreviation: CI, confidence interval.
This study illustrates an important and perhaps overlooked fact in the interpretation of multiple RCIs within a concussion test battery: that the percentage of normal, healthy individuals who are expected to show significant decline on at least 1 RCI in a multiple-test battery is higher than that percentage for individual RCIs. In particular, for a test battery that produces 7 or more uncorrelated RCIs, most normal individuals would demonstrate significant impairment on at least 1 RCI with 80% CIs for each. This concern is not unique to concussion tests or neuropsychological tests and rather is a statistical truism whenever one aggregates findings across a set of tests. The principle is the same as the inflated type I error rate resulting from multiple statistical comparisons but is easily forgotten in the context of clinical decisions. Although this language emphasizes the interpretation of RCIs given their widespread use for concussion assessment, the data also apply to the interpretation of single (eg, postinjury) scores.
Studies performed in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS have underlined the contribution of PD-1 and its ligands to dampening disease susceptibility or severity [24-26]. Moreover, blocking PD-1 using antibodies or knock-out mice led to an elevated number of CNS infiltrating immune cells, especially CD8 T cells [25-27]. We have previously shown [17] that although PD-L1 is barely detectable in the brain of normal controls, its expression is significantly increased in MS lesions, especially on astrocytes and microglia/macrophages [17]. We observed that although the very few CD8 T cells found in control brain are all PD-1 positive, the majority of infiltrating CD8 T cells in MS lesions do not express PD-1. Whether T cell infiltration into the inflamed CNS of MS patients is modulated by the BBB via the expression of PD-L1 and/or PD-L2 is still unresolved.
ORO and cuffing: Scored on a scale of 0 to 5 for ORO and haematoxylin staining; 0 is what would be expected in normal control white matter. Data is averaged from duplicate sections cut immediately before and after the serial sections cut.
PD-L1 is not detectable on brain endothelium of normal controls and MS patients. Micrographs showing brain sections stained for PD-L1 (green), caveolin-1 (red) and nucleus (blue) of one representative normal control (A-C) and two representative MS donors (E-G, I-K). In control subjects, PD-L1 immunoreactivity is not detectable (A). In contrast, PD-L1 is robustly expressed in MS lesions but it does not co-localize with the endothelial cell marker (E-G, I-K). Corresponding isotypes are shown in D, H and L. Scale bar: 25 μm.
PD-L2 is expressed on brain endothelial cells of normal controls, but down-regulated in MS lesions. Micrographs showing brain sections stained for PD-L2 (green), caveolin-1 (red) and nucleus (blue) of one representative normal control (A-C, M) and two representative MS donors (E-G, I-K, N). PD-L2 immunoreactivity is detected on all blood vessels visualized by caveolin-1 positive labeling in control subjects (C, M). However, in MS lesions, while PD-L2 reactivity is detected on blood vessels (E-G, N), a subset of blood vessels visualized by caveolin-1 labeling does not express detectable PD-L2 (I-K, N). Corresponding isotypes are shown in D, H and L. Scale bar: 25 μm (A-L), 400 μm (M, N). White arrows indicate examples of caveolin-1+ PD-L2- blood vessels, whereas orange arrows indicate examples of caveolin-1+ PD-L2+. O. Quantification of the percentage of blood vessels expressing PD-L2 in sections from normal controls (n = 3) and MS patients (n = 7). At least 6 blood vessels were counted for each section. Student's t-test: *** P < 0.001.
The 2020 Youth Theatre production will be another Barrington Stage commission, the world premiere musical The Supadupa Kid (July 30-Aug. 9), with book by Melvin Tunstall III, music by Joel Waggoner, and lyrics by Sukari Jones. Based on the novel by Ty Allan Jackson, the musical follows a normal kid after a freak accident grants him (and his bully) superpowers. Directed by Signe Harriday, the production will be presented outdoors and for free at the Common.
When normal rat and mouse embryo cells were treated with a cell free extract of S37 ascites tumour, morphological transformations occurred in both. The transformed cells readily induced lymphosarcoma-type tumours in the mice inoculated when newborn or young adults (8-12 weeks old), but not so readily in rats.
dd2b598166